- Home
- CLDI vs NERV Comparison
CLDI vs NERV Comparison
Compare CLDI & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLDI
- NERV
- Stock Information
- Founded
- CLDI 2014
- NERV 2007
- Country
- CLDI United States
- NERV United States
- Employees
- CLDI N/A
- NERV N/A
- Industry
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- CLDI Health Care
- NERV Health Care
- Exchange
- CLDI Nasdaq
- NERV Nasdaq
- Market Cap
- CLDI 18.1M
- NERV 18.3M
- IPO Year
- CLDI N/A
- NERV 2014
- Fundamental
- Price
- CLDI $2.16
- NERV $2.21
- Analyst Decision
- CLDI Strong Buy
- NERV Hold
- Analyst Count
- CLDI 3
- NERV 1
- Target Price
- CLDI $16.67
- NERV $5.00
- AVG Volume (30 Days)
- CLDI 3.5M
- NERV 25.4K
- Earning Date
- CLDI 11-12-2024
- NERV 11-05-2024
- Dividend Yield
- CLDI N/A
- NERV N/A
- EPS Growth
- CLDI N/A
- NERV N/A
- EPS
- CLDI N/A
- NERV N/A
- Revenue
- CLDI N/A
- NERV N/A
- Revenue This Year
- CLDI N/A
- NERV N/A
- Revenue Next Year
- CLDI N/A
- NERV N/A
- P/E Ratio
- CLDI N/A
- NERV N/A
- Revenue Growth
- CLDI N/A
- NERV N/A
- 52 Week Low
- CLDI $0.73
- NERV $2.07
- 52 Week High
- CLDI $26.30
- NERV $13.49
- Technical
- Relative Strength Index (RSI)
- CLDI 57.07
- NERV 39.78
- Support Level
- CLDI $2.10
- NERV $2.08
- Resistance Level
- CLDI $2.51
- NERV $2.35
- Average True Range (ATR)
- CLDI 0.43
- NERV 0.12
- MACD
- CLDI 0.04
- NERV -0.01
- Stochastic Oscillator
- CLDI 36.86
- NERV 28.87
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical stage immuno-oncology company pioneering the development and commercialization of novel, potent and efficient stem cell-based platforms for delivery and potentiation of oncolytic viruses for the treatment of cancer.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.